RLAY Key Statistics, Chart & Performance
The current stock price of RLAY is 7.71 USD. In the past month the price decreased by -7.66%. In the past year, price increased by 72.48%.
RLAY Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to RLAY. When comparing the yearly performance of all stocks, RLAY is one of the better performing stocks in the market, outperforming 90.62% of all stocks.
RLAY Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RLAY. While RLAY has a great health rating, there are worries on its profitability.
RLAY Financial Highlights
Over the last trailing twelve months RLAY reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS increased by 32.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.42% | ||
| ROE | -48.97% | ||
| Debt/Equity | 0 |
RLAY Forecast & Estimates
18 analysts have analysed RLAY and the average price target is 14.89 USD. This implies a price increase of 93.15% is expected in the next year compared to the current price of 7.71.
For the next year, analysts expect an EPS growth of 26.07% and a revenue growth -24.27% for RLAY
RLAY Ownership
About RLAY
Company Profile
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 188 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Company Info
RELAY THERAPEUTICS INC
60 Hampshire Street
Cambridge MASSACHUSETTS 02139 US
CEO: Sanjiv K. Patel
Employees: 188
Phone: 16173708837
RELAY THERAPEUTICS INC / RLAY FAQ
Can you describe the business of RELAY THERAPEUTICS INC?
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 188 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
What is the current price of RLAY stock?
The current stock price of RLAY is 7.71 USD. The price increased by 0.78% in the last trading session.
Does RLAY stock pay dividends?
RLAY does not pay a dividend.
What is the ChartMill technical and fundamental rating of RLAY stock?
RLAY has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the market expecting RLAY stock to perform?
18 analysts have analysed RLAY and the average price target is 14.89 USD. This implies a price increase of 93.15% is expected in the next year compared to the current price of 7.71.
Can you provide the market cap for RELAY THERAPEUTICS INC?
RELAY THERAPEUTICS INC (RLAY) has a market capitalization of 1.34B USD. This makes RLAY a Small Cap stock.
Can you provide the upcoming earnings date for RELAY THERAPEUTICS INC?
RELAY THERAPEUTICS INC (RLAY) will report earnings on 2026-02-19, after the market close.